Valeo Pharma receives FDA OK for ethacrynate sodium

The Food and Drug Administration has given the green light to Canadian specialty pharmacy firm Valeo Pharma's ethacrynate sodium.

The drug is indicated to treat edema and swelling caused by congestive heart failure, acute pulmonary oedema, renal oedema, hepatic cirrhosis with ascites or other medical conditions will soon have a new treatment available.

The product will be available in a dosage strength of 50 mg.  

"We are pleased to have received the FDA's authorization to begin commercializing ethacrynate sodium in the United States. This is the first regulatory approval we have received from the FDA and we expect sales of ethacrynate sodium to start this summer,” said Steve Saviuk, Valeo's president and CEO.